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doi:10.1016/j.jtcvs.2008.02.020Objective: We identified changes in Jumonji (JARID2) expression in failing human
hearts and determined its effects on expressions of atrial natriuretic factor (ANF),my-
osin light chain 2a (MLC2A), and a myosin heavy chain (MHCA), genes associated
with both human heart failure and the fetal gene program.
Methods: Left ventricular outflow tract cardiac biopsy samples were taken from 31
patients with aortic valvular stenosis. Hearts were grouped according to left ventric-
ular size and function: nonfailing hearts (undilated with good function) and failing
hearts (dilated with poor function). Protein levels were determined by Western blot-
ting, and messenger RNA transcript levels by ratiometric reverse transcriptase–poly-
merase chain reaction. Luciferase assays in HL-2 cells were used to assess effects of
Jarid2 on Anf, Mlc2a, and Mhca transcriptions. Chromatin immunoprecipitation
was used to detect interaction of JARID2 with specific target-gene promoters.
Results: JARID2 and MHCA expressions were reduced in failing hearts, whereas
MLC2A and ANF were increased. In HL-2 cell culture, Jarid2 suppressed Anf and
Mlc2a but enhanced Mhca. Jarid2 expression was reduced by cyclic mechanical
stress, with concomitant increased Anf and Mlc2a and decreased Mhca expressions,
reproducing the expression profile found in decompensated human pressure overload.
Conclusion: Jumonji expression is reduced by mechanical stress in human heart fail-
ure from aortic stenosis. JARID2 regulates ANF, MLC2A, and MHCA transcription
and contributes to reexpression of the fetal gene program in decompensated aortic ste-
nosis. JARID2 appears important in transcriptional regulation of fetal genes and may
emerge as a diagnostic marker for left ventricular decompensation in aortic stenosis.
T
he initial response of the heart to hemodynamic overload is cardiac hypertro-
phy. When overload continues, however, the adaptive hypertrophic changes
become deleterious, with progression to decompensated heart failure.1 Heart
failure is accompanied by structural and physiologic changes that include myocyte
hypertrophy, interstitial fibrosis, and altered contractile function.2 The phenotypic
changes are mediated by the altered expression of particular classes of genes. These
include genes encoding contractile proteins and proteins involved in calcium regula-
tion and excitation–contraction coupling, together with reexpression of the fetal gene
program.3 This involves the ventricular reexpression of fetal and neonatal isoforms of
contractile and other proteins, such as atrial natriuretic factor (ANF). These findings
have been reported both in heart failure models3,4 and in patients with heart failure.5-7.
Within the human myocyte contractile apparatus, a myosin heavy chain (a-MHC) is
the predominant myosin heavy chain isoform expressed in human ventricular myocar-
dium, but messenger RNA (mRNA) expression of the gene for a-MHC, MHCA, is
greatly reduced in failing hearts.8,9. There are also changes in expressions of genes
for myosin light chain 2 (MLC-2) in both human heart failure and animal modelsThe Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 3 709
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CDAbbreviations and Acronyms
a-MHC 5 a myosin heavy chain
ANF 5 atrial natriuretic factor
ANF 5 human gene for atrial natriuretic factor
Anf 5 mouse gene for atrial natriuretic factor
b-MHC 5 b myosin heavy chain
bp 5 base pairs
GAPDH 5 glyceraldehyde 3-phosphate dehydrogenase
GFP 5 green fluorescent protein
JARID2 5 human Jumonji gene
Jarid2 5 mouse Jumonji gene
kb 5 kilobase
LV 5 left ventricle
LVEF 5 left ventricular ejection fraction
MHCA 5 human gene for a myosin heavy chain
Mhca 5 mouse gene for a myosin heavy chain
MLC-2 5 myosin light chain 2
MLC2A 5 human gene for myosin light chain 2a
Mlc2a 5 mouse gene for myosin light chain 2a
mRNA 5 messenger RNA
PCR 5 polymerase chain reaction
RT-PCR 5 reverse transcriptase–polymerase chain
reaction
of the disease.10 Although several transcriptional regulators
of ANF, the gene for MLC-2a (MLC2A), andMHCA expres-
sions have been identified in the hypertrophied and failing
heart (eg, GATA4, MEF2, Nkx-2.5), the precise molecular
pathways responding to hemodynamic overload and to me-
chanical stress remain to be defined.11,12
The human Jumonji gene (JARID2) encodes a 1234–
amino acid protein homologous to human retinoblastoma-
binding protein 2.13 JARID2 contains nuclear localization
signals and an AT-rich interaction domain for DNA binding
similar to other transcription factors, such as dead ringer
(Dmel\retn) in Drosophila and SWI1 in yeast,14,15 but it
does not have a well-defined consensus binding se-
quence.16,17 JARID2 has an exclusively nuclear distribution
and has recently been identified as a transcriptional regulator
of ANF,16 a-MHC,18 and cyclin D1.19-21
The mouse Jumonji gene (Jarid2) has been identified as
an important factor for normal cardiac development in
mice22,23; Jarid2 is expressed in cardiac and vascular tissues
in adult mice, especially in the interventricular septum, ven-
tricular free wall, and outflow tract. In Jarid22/2 mice, mal-
formations are found in the interventricular septum and
outflow tract (ventricular septal defect and double-outlet right
ventricle), and the expression patterns of several cardiac-spe-
cific genes are disrupted.22,23 Ventricular ANF expression
normally declines rapidly just before birth, whereas atrial ex-
pression is maintained,24 but ANF expression remains high in
the Jarid22/2 murine ventricle.22 Similarly, ventricular
MLC2A expression falls during normal cardiac chamber710 The Journal of Thoracic and Cardiovascular Surgery c Sepdevelopment25 but persists in Jarid22/2 hearts. There is fail-
ure of the normal switching of b myosin heavy chain (b-
MHC) to a-MHC in the murine ventricle near birth, with
higher ventricular b-MHC levels and reducedMHCA expres-
sion in Jarid22/2 mice.22
In view of these findings, we considered that JARID2
expression might be altered in patients with valvular heart
disease and that JARID2 might contribute to the regulation
of ANF, MLC2A, and MHCA. Patients with aortic stenosis
manifest a wide spectrum of left ventricular (LV) function,
from normal to severely impaired. In this study, our objectives
were to elucidate the molecular response of human LV myo-
cardium to increased afterload in aortic stenosis and to explore
the diagnostic potential of these changes to influence the
timing of cardiac surgery before hypertrophy devolves into
dilatation.We elected to investigate several intuitively logical
genes that are associated both with an increase in afterload in
experimental animals and with altered cell-cycle influence
(eg, ventricular septal defects) in gene-knockout mice.
Materials and Methods
Procurement of Human Myocardial Tissue
Under a protocol approved by the Oxford Radcliffe Research Ethics
Committee and after informed consent, human myocardial biopsy
samples were obtained from the LV outflow tract of selected pa-
tients undergoing isolated aortic valve replacement for aortic steno-
sis (ie, with pressure-overload cardiac hypertrophy). The specimens
were obtained from the endocardium of the subvalvular region,
away from the conduction tissue and in an area accessible by trans-
catheter endocardial biopsy. Patients with associated coronary ar-
tery disease were excluded. All patients underwent preoperative
transthoracic echocardiography to determine LV ejection fraction
(LVEF) and LV dimensions.26 Study patients were selected to
fall clearly into one of two groups on the basis of the echocardio-
graphic assessment of LV function. The failing heart group (n 5
15) had reduced LVEF and increased LV dimensions; the nonfail-
ing group (n 5 16) had preserved LVEF and normal LV dimen-
sions (Table 1).
TABLE 1. Preoperative echocardiographic assessment and
New York Heart Association functional class of patients
Nonfailing Failing
Reference
range
No. of patients 16 15
Age (y) 61.6 6 15.2 59.7 6 18.7
LV end-diastolic
diameter (cm)
4.77 6 0.49 6.44 6 0.53* 3.5–5.6
LV end-systolic
diameter (cm)
2.84 6 .37 4.3 6 0.55* 2.5–4.1
LV ejection fraction (%) 58.33 6 5.2 35.4 6 4.92* 55–75
New York Heart Association
functional class
1.8 2.7*
Values are mean 6 SD. LV, Left ventricular. *P , .05 versus nonfailing.tember 2008
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Myocardial biopsy samples were frozen and ground under liquid
nitrogen and stored at 280C. Protein was extracted into a urea
buffer (9-mol/L urea, 2% sodium dodecylsulfate, 2% 3-[(3-cholami-
dopropyl)dimethylammonio]-1-propanesulfonate, 0.5% Triton X-
100 [The Dow Chemical Company, Midland, Mich], 20–mmol/L
dithiothreitol, and 50-mmol/L tris(hydroxymethyl)aminomethane
hydrochloride, pH 7.4), and the concentration of each sample was
determined by Bradford assay (Sigma–Aldrich Co, St Louis, Mo).
Human JARID2 gene product in myocardial protein isolates was de-
tected by Western blotting. Sodium dodecylsulfate–polyacrylamide
gels were loaded with 100-mg aliquots of protein for electrophoresis
and blotting. Blots were probed with a rabbit polyclonal primary an-
tibody raised against a synthetic peptide of human JARID2 (acces-
sion NP004964; Eurogentec Ltd, Hythe, UK) that detects
a predicted 145-kDa band for JARID2, a mouse anti–human ANF
antibody (Abcam plc, Cambridge, UK) was used to detect ANF,
and gel loading was confirmed by reprobing blots with a b-actin an-
tibody (Abcam). Blots were probed with a horseradish peroxidase–
labeled secondary antibody (Dako A/S, Glostrup, Denmark) and
analyzed by chemiluminescence (Amersham Biosciences Europe
GmbH, Freiburg, Germany) on a densitometer (Bio-Rad Laborato-
ries Inc, Hercules, Calif) to allow calculation of the relative intensity
of each band with proprietary software.
Ratiometric Reverse Transcriptase–Polymerase
Chain Reaction for MHCA and MLC2A mRNA
Expressions
Total RNA was extracted from myocardial biopsy samples with the
QIAGEN RNeasy extraction protocol (QIAGEN Ltd, Crawley,
United Kingdom), and 1 mg total RNA was reverse transcribed ac-
cording to the manufacturer reverse transcriptase–polymerase chain
reaction (RT–PCR) protocol with oligodeoxythymidine primers
(Promega Corporation, Madison, Wis); PCR primer sequences
and conditions are shown in Table 2. A fragment of 272 base pairs
(bp) at the 30 end of humanMLC2A (accession M94547) and a 296-
bp fragment from the 30 end of human MHCA (accession D00943)
were amplified, and the identities of the products were confirmed
by sequencing. Amplified sequences were separated by gel electro-
phoresis and analyzed on a GeneGnome imaging system (Syngene;
Synoptics Ltd, Cambridge, UK) to measure band intensity againstThe Journal of Thoglyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression
within each sample.27
Promoter–Luciferase Constructs and Luciferase
Assays
The 2-kilobase (kb) MLC2A promoter was produced by PCR am-
plification of a described promoter region28 from genomic DNA
of HEK293 cells and insertion of the amplified sequence into the
BamHI and EcoRI sites of pGL3 Basic Vector (Promega). The
5.6-kb MHCA promoter was provided by Dr J. Gulick and Prof
J. Robbins (The Cleveland Clinic, Cleveland, Ohio),29 and the
3.7-kb ANF promoter–luciferase construct was supplied by Prof
M. Nemer (Institut de Recherches Cliniques de Montre´al, Mon-
tre´al, Quebec, Canada).11 Luciferase assays were performed by co-
transfecting equimolar amounts of each construct and 40 pg of
pRL-CMV Vector (Promega_ into HL-2 cells with the Effectene
reagent (QIAGEN); vector-only control experiments were per-
formed concurrently. Cell lysates were assayed for Photinus and
Renilla luciferase activities after 48 hours with the Promega dual-
luciferase assay system; Photinus luciferase activity was normal-
ized against Renilla activity to control for variable transfection
efficiencies.
Modified Chromatin Immunoprecipitation of jmj–
Promoter Complexes
HL-2 cells were cotransfected with equimolar amounts of promoter–
luciferase construct and jmj–green fluorescent protein (GFP)22 or
GFP vector alone, and a modified chromatin immunoprecipitation
assay was performed as previously described30 after 48 hours. For
each precipitation reaction, a third of the lysate was used as a positive
control, and total DNA was ethanol precipitated. Another third of
the lysate was diluted 10-fold, and protein–DNA complexes were
precipitated by an anti-GFP antibody (Upstate Biotechnology, Inc,
Lake Placid, NY) and protein A–agarose. The remaining third of
the lysate was processed in parallel with an irrelevant (anti-Myc) an-
tibody. PCR amplification of the luciferase gene was performed on
the washed immunoprecipitated complexes.30
Jarid2 Expression in Stressed HL-2 Cells
Murine HL-2 cells, derived fromHL-1 cells, were kindly donated by
Dr William Claycomb (Louisiana State University Medical Center,TABLE 2. Primer sequences and polymerase chain reaction conditions
Primer Primer sequence (50–30) Product size (bp) Annealing temp (C) No. of cycles
MHCA human F CTGGAGGCCGAGCAGAAG 296 58 33
MHCA human R CTCTTGGCTCGAAGCTTGTT
Mhca mouse F CAGCTTGTTGACCTGGGACT 361 58 33
Mhca mouse R AGAGCAGATCGCCCTCAAG
MLC2A human F GTCTTCCTCACGCTCTTTGG 272 58 33
MLC2A human R CCTGCCCCTCATTCCTCT
Mlc2a mouse F TGACCTCAGCCTGTCTACTCC 342 58 33
Mlc2a mouse R AAGTGTTCCGGAGGAAGAGC
Mouse Jarid2 F GATTGCACAAGCAGAAGCAA 458 58 33
Mouse Jarid2 R TTGGTGTGGGTTTGTTGAGA
All polymerase chain reactions were performed with Taq polymerase with an initial 1-minute denaturation step at 94C, followed by cycles of 30-second de-
naturation at 94C, 30-second annealing, and 45-second extension at 72C. bp, Base pairs. F 5 forward primer, R 5 reverse primer.racic and Cardiovascular Surgery c Volume 136, Number 3 711
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Lenexa, Kan) as previously described.31 Cells were subcultured into
gelatin- and fibronectin-coated FlexerCell plates (Flexcell Interna-
tional Corporation, Hillsborough, NC) for 24 hours, and then con-
fluent layers of cells were subjected to 7.5% stretch at 60 Hz for
up to 24 hours on a FlexerCell-4000 tension system (Flexcell). Ex-
periments were performed in triplicate on three separate occasions.
Cells were harvested by trypsinization and centrifugation, then
washed in ice-cold phosphate-buffered saline solution before total
RNA extraction with the QIAGEN RNeasy kit or total protein ex-
traction into Radio Immuno Precipitation Assay (RIPA) buffer.
RT–PCR was performed on 1-mg aliquots of total RNA with the
primers and conditions shown in Table 2 to amplify 30-terminal frag-
ments of murine Jarid2 (458 bp), Mlc2a (342 bp), and Mhca (361
bp). Amplicon identity was confirmed by sequencing. GAPDH
RT-PCR was performed on the same samples, and relative target
mRNA expressions were calculated as before.
Statistical Analysis
Data are expressed as a mean 6 SD. Groups were compared with
Student t test or analysis of variance as appropriate.
Results
Jumonji Expression Reduction in Human Heart
Failure
JARID2 protein was reduced by 60% (P , .005) in failing
hearts relative to nonfailing hearts (Figure 1, A and B). Ven-
tricular ANF protein was expressed only in failing hearts
(Figure 1, A). MLC2A mRNA was not detectable by RT–
PCR in nonfailing hearts but was present in failing hearts
(Figure 1, A). There was a 42% decrease (P , .005) in
MHCAmRNA expression in failing hearts relative to nonfail-
ing hearts (Figure 1, A and C).
Jumonji Regulation of Anf, Mlc2a, and Mhca
Expressions in a Dose-Dependent Manner
In murine HL-2 cell cotransfection experiments, Jumonji in-
duced dose-dependent suppression of Anf (Figure 2, A, left
columns) and Mlc2a (Figure 2, B) expressions. In contrast,
Jumonji enhanced Mhca expression in a dose-dependent
manner (Figure 2, C).
Jumonji interaction With Anf, Mlc2a, and Mhca
Promoters in HL-2 cells
With a modified chromatin immunoprecipitation assay,
Jarid2–GFP was immunoprecipitated with target promoter–
luciferase constructs. PCR for luciferase in precipitated
protein–DNA complexes confirmed that Jarid2–GFP binds
to Anf, Mlc2a, and Mhca promoters (Figure 3).
Reductions of Jarid2 and Mhca Expressions but
Increases of Anf and Mlc2a Expressions With
Mechanical Stress
Expression of mRNA in stressed HL-2 cell layers was as-
sessed by ratiometric RT–PCR. Mechanical stress induced
a time-dependent reduction in Jarid2 expression but had712 The Journal of Thoracic and Cardiovascular Surgery c Sep0
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Figure 1. Jumonji (JARID2) levels are decreased in failing human
ventricular biopsy samples. A, Representative Western blots (top
panel) and reverse transcriptase–polymerase chain reaction
(RT-PCR) gels (lower panel) from nonfailing and failing hearts. Ju-
monji protein expression is reduced in ventricular biopsy samples
from failing hearts relative to nonfailing hearts; conversely, atrial
natriuretic factor (ANF) is not detectable in nonfailing ventricles
but is present in failing hearts. Reverse transcriptase–polymerase
chain reaction for a myosin heavy chain (aMHC) messenger RNA
shows decreased expression in failing hearts, whereas myosin
light chain 2a (MLC2a) mesenger RNA is reexpressed in ventricu-
lar tissue from failing hearts. B, Western blot densitometry shows
60% decrease in Jumonji protein levels in failing relative to non-
failing hearts. Asterisk indicates P < .005. C, Ratiometric reverse
transcriptase–polymerase chain reaction shows 42% decrease in
a myosin heavy chain messenger RNA expression in failing
hearts. Asterisk indicates P < .005. GAPDH, Glyceraldehyde 3-
phosphate dehydrogenase.tember 2008
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decreased by 85% after 24 hours with mechanical stress rel-
ative to baseline (P , .01, Figure 4, B). Changes in Jarid2
expression were accompanied by increased ANF protein
and MLC2A mRNA levels and decreased MHCA
expression (Figure 4, A).
Discussion
We studied JARID2 expression in the failing human heart,
in which altered ventricular ANF, MLC2A, and MHCA ex-
pressions are well recognized. We also examined the inter-
actions of Jarid2 with specific target promoters and other
transcription factors in murine cell culture. In patients with
aortic stenosis, we have shown the reexpression of a fetal
gene program in cardiac myocytes subjected to increased
afterload.
Figure 2. Murine gene Jarid2 mediates suppression of atrial
natriuretic peptide (ANF) and myosin light chain 2a (MLC2a)
gene transcription but promotion of a myosin heavy chain
(aMHC) gene transcription. Control level of transcription of each
promoter–luciferase construct in presence of 0.25 pmol empty
vector is set at 100, and other values are expressed relative to con-
trol. Increasing amounts of transfected plasmid from 0.1 to 0.25
pmol are denoted by black wedges. Jarid2 induces dose-depen-
dent supression of ANF (left column) and MLC2a (central column)
transcription but dose-dependent activation of aMHC transcrip-
tion (right column). Data shown represent at least three indepen-
dent experiments, each performed in triplicate. Asterisk indicates
P < .005 versus control. pEGFP, Plasmid enhanced green fluores-
cent protein.The Journal of ThoLimitations of the Study
All patients with aortic stenosis have LV hypertrophy de-
velop, so their myocardium cannot be considered normal
even when ventricular function is preserved. As such, it
may not be possible to extrapolate our findings to all cases
of heart failure. For this clinical study, we selected patients
in whom well-preserved LV function could clearly be differ-
entiated from those with LV dilatation and heart failure in
response to afterload.
Regulation of MHCATranscription by JARID2
The protein a-MHC has higher adenosine triphosphatase
activity than does b-MHC and produces faster shortening
velocity of cardiac myofibers. Lower ventricular systolic
resistance and greater contractile force are observed in hearts
with a-MHC as the predominant myosin heavy chain iso-
form.32,33. The a-MHC levels are greatly reduced in failing
hearts, regardless of etiology, and this has been proposed
as an important factor for reduced myocardial contractility
in heart failure.8,34 Several regulatory elements and their
binding factors, including GATA4 andMEF2A, that promote
cardiac expression of MHCA have been identified,35 but
molecular mechanisms underlying the suppression of
ANF-Luc
MLC2a-Luc
αMHC-Luc
a
n
t
i
-
G
F
P
a
n
t
i
-
M
y
c
I
n
p
u
t
V
e
c
t
o
r
 
o
n
l
y
P
C
R
 
n
e
g
.
 
c
o
n
t
.
Figure 3. Coimmunoprecipitation of jmj–green fluorescent protein
(GFP) complex with atrial natriuretic factor (ANF), myosin light
chain 2a (MLC-2a), and a myosin heavy chain (aMHC) promoters.
An anti–green fluorescent protein antibody was used to precipi-
tate jmj–promoter complexes formed by cotransfection of
Jarid2–GFP, and target promoter–luciferase construct into HL-2
cells and polymerase chain reaction for luciferase (Luc) con-
firmed Jarid2–GFP binding to target promoter; target promoters
are for atrial natriuretic factor, myosin light chain 2a, andamyosin
heavy chain. Negative controls (neg. cont.) are GFP plasmid vector
only and irrelevant antibody (anti-Myc); cell lysates (Input) are
used as positive controls.racic and Cardiovascular Surgery c Volume 136, Number 3 713
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CDMHCA expression in heart failure remain unknown. We have
shown that JARID2 interacts with theMHCA promoter to ac-
tivate MHCA transcription in a dose-dependent manner. Our
results differ from those of Kim and associates,18 who used
a small promoter fragment (368 bp) to show transcriptional
suppression by JARID2,whereas we used a much larger frag-
ment (.5 kb). The suppression apparent on the minimal pro-
moter may not be significant when a larger regulatory region
is used. We also have shown that JARID2 expression is de-
creased in human heart failure, and this may contribute to
the reduction in a-MHC levels seen in failing hearts. This
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Figure 4. Gene Jarid2 is supressed by mechanical stress. A, re-
verse transcriptase–polymerase chain reactions for Jarid2, myo-
sin light chain 2a (MLC2a), a myosin heavy chain (aMHC), and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH),with West-
ern blotting for atrial natriuretic protein (ANF),were performed on
extracts of HL-2 cells subjected to mechanical stress up to 24
hours. These gels show time-dependent reductions in Jarid2
and a myosin heavy chain messenger RNA expressions and
time-dependent increases in myosin light chain 2a messenger
RNA and atrial natriuretic factor protein expressions. B, Ratiomet-
ric reverse transciptase–polymerase chain reaction shows that
Jarid2 expression decreases with longer duration of mechanical
stress. Asterisk indicates P < .005 relative to baseline (repeated
measures analysis of variance).714 The Journal of Thoracic and Cardiovascular Surgery c Sepfinding is compatibile with the reduced ventricularMhca ex-
pression found in Jarid22/2 mice.22 Thus JARID2 has a role
in the regulation of MHCA gene expression.
Regulation of MLC2ATranscription by JARID2
The protein MLC-2a is seen throughout the fetal heart but is
restricted to the atria in later development.36 MLC2A expres-
sion in the ventricular myocardium instead of MLC2V pro-
duces a dilated cardiomyopathy characterized by impaired
contractility and reduced ventricular ejection fraction.37 It ap-
pears that the restriction of MLC2A expression to the adult
atrium is achieved through suppression of ventricular
MLC2A transcription.38 We have shown that JARID2 sup-
presses MLC2A transcription, suggesting that JARID2 con-
tributes to the normal mechanism for suppression of
ventricular MLC2A expression. We have also shown low-
level MLC2A expression in the ventricular myocardium of
the failing hearts; this may be related to reduced jmj levels.
Regulation of ANF Transcription by JARID2
During fetal development, ANF is expressed in both atria and
ventricles, but it is restricted to the atria near birth.39 The min-
imal mammalian Anf promoter sufficient for correct cham-
ber-specific expression in mice40 contains binding sites for
SRF, GATA4, and Nkx-2.5 and was included in the construct
used in this study. ANF expression is regulated by Nkx-2.5
and GATA4, and mutation of either binding site results in
a failure of ANF transcription.38 This finding is in agreement
with those of previous studies with cultured cardiomyocytes,
which showed that mutation of the NKE resulted in upregu-
lation of ANF promoter activity in ventricular cells.12 Small
and Kreig38 interpreted these results as an indication that
theGATA and NKE sites are recognition sequences for an un-
identified suppressor of ventricular ANF expression. Trans-
genic mice that overexpress myocardial Nkx-2.5 show
persistent ventricular ANF expression,41 suggesting that ven-
tricular Nkx-2.5 competes with a putative suppressor factor.
Studies of the ANF promoter suggest that, as with MLC2A,
atrial-restricted expression of ANF is achieved through inhi-
bition of ventricular expression. Our group and others16 have
independently identified JARID2 as a suppressor of ANF
transcription. We have shown that a decrease in JARID2
levels, as found after mechanical stress and in human heart
failure, is associated with increased ANF expression. This ob-
servation, together with the finding that JARID2 associates
with the ANF promoter in vitro, strongly suggests that in-
creased ANF expression in failing hearts is at least partly
the result of removal of suppression by declining JARID2.
Regulation of Jarid2 Levels by Mechanical Stress
Heart failure may follow hemodynamic overload. Myocytes
are direct sensors of hemodynamic load that may be mim-
icked in vitro by subjecting cultured cell layers to mechanical
stress. Murine HL-2 cells subjected to mechanical stress intember 2008
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Jarid2 levels. RT–PCR of stressed cell extracts showed in-
creased Mlc2a and decreased Mhca expressions. Western
blotting of parallel samples showed increased ANF in
stressed cells. This is consistent with our observations that
Jarid2 suppressesMlc2a and ANF expressions while activat-
ing Mhca expression, and it is also consistent with the upre-
gulation of ANF expression by mechanical stress.
Decreased Jumonji Protein Expression in Failing
Human Hearts
JARID2 is a factor responsive to mechanical stress: this led us
to examine JARID2 in pressure-overload induced heart failure.
Immunoblot analysis showed decreased JARID2 protein prod-
uct inLVbiopsy samples from failing hearts relative to samples
from nonfailing hearts with preserved LV function. These
changes in protein level are consistent with those observed
for mRNA in stressed cultured cells. We speculate that the
stimuli for reduced JARID2 expression are chamber dilatation
and increased wall stress, and reduced JARID2 expression in
turn leads to misexpressions of ANF, MLC2A andMHCA.
Conclusions
This study has demonstrated a previously unrecognized reg-
ulatory function of JARID2 with possible roles in regulating
ANF, MLC2A, and MHCA genes in heart failure. We have
shown that murine Jarid2 expression is downregulated in re-
sponse to mechanical stress and that this is associated with
decreased Mhca expression but increased Mlc2a and Anf ex-
pressions. JARID2 is a crucial factor for the regulation of
ANF, MLC-2a and a-MHC proteins. Normal ANF and
MLC2A expressions may be controlled by a balance among
the actions of JARID2, GATA4, and Nkx-2.5; in the failing
human heart, reduced JARID2 expression thus contributes
to increased ANF and MLC2A expressions and to decreased
MHCA expression, which may ultimately contribute to the
contractile insufficiency.
Future Work
It may be that the LV responds to increased afterload by re-
expressing the fetal gene program. Our study suggests that
this occurs at or after the point at which the LV begins to di-
late, and that human JARID2 is an important transcriptional
regulator central to the timing of this breaking point. This
suggests we might perform JARID2 characterization by en-
domyocardial biopsy during the assessment of the severity
of aortic stenosis (while LV function remains well pre-
served). When JARID2 or cell cycle or fetal reprogramming
genes are expressed, the cardiologist could argue that the time
for aortic valve replacement has arrived. A panel of fetal re-
programming genes could be used to pinpoint the breaking
point at which LV hypertrophy switches to LV dilatation.
Genetic studies could thus be a useful clinical tool when
recommending the timing of aortic valve replacement.The Journal of ThoWe now aim to study a full range of patients with aortic
stenosis and regurgitation. We plan to use logistic regression
analysis to further define the relationship between JARID2
and LVEF.
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and Dr Y. Lee (University of Wisconsin School of Medicine and
Public Health, Madison, Wis) for their kind gift of plasmids.
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